Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Future directions in gastrointestinal cancer

Thorsten O. Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, outlines the changing treatment landscape of patients with gastrointestinal malignancies including combining chemotherapy and immune checkpoint blockade, emerging targeted therapies including the FGFR inhibitor bemarituzumab, as well as HER2-targeting agents in patients with HER2 alternations. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.